EUVIMEDEUVIMED entdecken
Open Access

Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology

Christopher J Schwartz iD, Tanner Mack, William Travis, Hong Zhang, Nour Abuhadra, Risa Kiernan iD, Giacomo Montagna iD, Edi Brogi, Fresia Pareja, Hannah Y Wen, Dara S Ross

JCO Precision Oncology · 2026-08 · 10 (8)

DOI: 10.1200/po-26-00416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Christopher J Schwartz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Primary breast neuroendocrine carcinomas (NECs) are rare, high-grade malignancies that are frequently grouped with invasive breast carcinomas with neuroendocrine differentiation (IBC-NED), despite uncertain biological equivalence. We sought to define the clinicopathologic, immunophenotypic, and genomic features of breast NEC and to determine whether they represent a biologically distinct entity. METHODS We performed a retrospective analysis of 24 primary breast NECs and compared them with 28 grade-matched IBC-NEDs. Clinicopathologic features, treatment response, and outcomes were evaluated. Immunohistochemical profiling included neuroendocrine and breast lineage markers and retinoblastoma (Rb) expression. Targeted tumor-normal next-generation sequencing was performed in a subset of NEC (n = 10) and IBC-NED (n = 7) to characterize genomic alterations and pathway-level differences. RESULTS Breast NECs were predominantly estrogen receptor (ER)–negative/human epidermal growth factor receptor-2–negative (63%) and frequently exhibited small cell morphology. Despite radiographic response to neoadjuvant chemotherapy, no patients achieved pathologic complete response. Immunophenotypically, NECs demonstrated diffuse neuroendocrine marker expression and frequent loss of Rb protein (93%), consistent with RB pathway disruption. Compared with IBC-NED, NECs showed significantly lower ER expression and reduced GATA3 positivity. Genomically, NECs were enriched for TP53 alterations (90% v 33%, P < .05) and more frequently harbored RB1 alterations (60% v 14%), with concurrent TP53 / RB1 alterations in 50% of cases. Alterations in the PI3K pathway were also observed in NECs. By contrast, IBC-NED demonstrated recurrent luminal-type copy-number alterations, including amplifications in FGFR1 and CCND1 . CONCLUSION Breast NEC is characterized by a distinct clinicopathologic and molecular profile compared with grade-matched IBC-NED, defined by frequent TP53 and RB1 alterations, RB pathway disruption, and limited response to neoadjuvant therapy. These findings support classification of breast NEC as a biologically distinct subtype and highlight potential avenues for biomarker-driven therapeutic strategies in this rare malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, NeuroendocrineHumansFemaleRetrospective StudiesMiddle AgedAgedAdultBiomarkers, Tumor

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Christopher J Schwartz, Risa Kiernan, Giacomo Montagna

Förderung

  • NCI NIH HHS
  • FDA HHS

Zitieren

APA

Schwartz, C. J., Mack, T., Travis, W., Zhang, H., Abuhadra, N., Kiernan, R., Montagna, G., Brogi, E., Pareja, F., Wen, H. Y., & Ross, D. S. (2026). Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-26-00416

Vancouver

Schwartz CJ, Mack T, Travis W, Zhang H, Abuhadra N, Kiernan R, et al. Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-26-00416

BibTeX
@article{Schwartz2026,
  author = {Schwartz, Christopher J and Mack, Tanner and Travis, William and Zhang, Hong and Abuhadra, Nour and Kiernan, Risa and Montagna, Giacomo and Brogi, Edi and Pareja, Fresia and Wen, Hannah Y and Ross, Dara S},
  title = {Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {8},
  doi = {10.1200/po-26-00416}
}
Kostenlos starten →